COVID-19 vaccination in patients with long QT syndrome

Cheng I. Wu, Peter J. Schwartz, Michael J. Ackerman, Arthur A.M. Wilde

Research output: Contribution to journalReview articlepeer-review


Patients with long QT syndrome (LQTS) face potential threats from COVID-19 vaccination. Fever is one of the issues that is not uncommon after vaccination, and it usually takes place within 2 days. In particular, patients with type 2 LQTS based on trafficking-deficient variants are probably vulnerable to arrhythmogenicity under febrile conditions. Furthermore, myocarditis is one of the rare complications that is possibly associated with acquired QT prolongation and puts patients with LQTS at risk of life-threatening arrhythmia. Moreover, postural orthostatic tachycardia syndrome is another rare condition that, perhaps, poses LQTS patients susceptible to life-threatening arrhythmia when QT interval does not shorten optimally during tachycardia. In this review, we recommended prudent measurements to beneficially reduce the risk for patients with LQTS when vaccination or booster doses are eligible.

Original languageEnglish (US)
Pages (from-to)706-709
Number of pages4
JournalHeart Rhythm O2
Issue number6
StatePublished - Dec 2022


  • COVID-19
  • Inherited cardiac arrhythmias
  • Long QT syndrome
  • SARS-CoV-2
  • Vaccinations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'COVID-19 vaccination in patients with long QT syndrome'. Together they form a unique fingerprint.

Cite this